ALB and Alzheimer disease: In the single-arm ATTIRE feasibility study of 79 patients at 10 sites, we demonstrated that 20% HAS infusions restored serum albumin levels to >30 g/dL and improved ex vivo immune function in AD/ACLF patients by day 3 of study participation through antagonism of PGE2.6